Article info

Download PDFPDF

TP007/#1383  A phase II study of induction PD-1 blockade (nivolumab) in patients with surgically completely resectable mismatch repair deficient endometrial cancer (NIVEC)
Free

Authors

Citation

Alsomairi A, Lee J, Lee YJ, et al
TP007/#1383  A phase II study of induction PD-1 blockade (nivolumab) in patients with surgically completely resectable mismatch repair deficient endometrial cancer (NIVEC)

Publication history

  • First published November 7, 2023.
Online issue publication 
November 07, 2023

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.